News Briefing channel feed

In­cyte ponies up $12M to set­tle char­i­ty foun­da­tion kick­back claims; US ex­er­cis­es op­tion for more dos­es of mon­key­pox vac­cine

5 years ago

Keytru­da gets ac­cel­er­at­ed OK in HER2-pos­i­tive gas­tric can­cer; Twin­Strand gets $50M to hunt for 'nee­dles in a haystack'

5 years ago

Clo­vis spikes ovar­i­an can­cer com­bo af­ter 'un­der­whelm­ing' ef­fi­ca­cy; Servi­er wins pri­or­i­ty re­view for Tib­so­vo ex­pan­sion

5 years ago

Se­quenc­ing up­start rais­es $273M ahead of IPO; Ac­er­a­gen ac­quires high­ly-an­tic­i­pat­ed Far­ber dis­ease treat­ment

5 years ago

News brief­ing: Gy­ro­scope and Ta­laris set IPO terms; FDA grants ex­pand­ed nod to Chiesi's sick­le cell drug

5 years ago

J&J bids for EU OK on Leg­end CAR-T; FDA ex­tends re­view pe­ri­od for Arde­lyx's phos­pho­rus con­trol drug

5 years ago

Galera claims pos­i­tive up­date in pan­cre­at­ic can­cer but does­n't re­port p-val­ues; Am­gen launch­es Cana­di­an fund in tan­dem with CCRM

5 years ago

BeiGene's late stage tri­al shows promis­ing num­bers; Am­gen to study so­tora­sib dosage af­ter FDA rec­om­men­da­tion

5 years ago

News brief­ing: Af­ter lengthy odyssey, Rea­ta is fi­nal­ly ready for its close­up; MIT's Hock­field takes board seat at Reper­toire

5 years ago

X-Bi­otix sus­pends R&D ef­forts amid dearth of fi­nanc­ing for an­tibi­otics re­search; Ver­tex picks a pain drug for mid-stage stud­ies

5 years ago

J&J's Trem­fya scores 5-year pso­ri­a­sis win in AAD da­ta dump; Roche, Re­gen­eron drugs among lat­est to earn EU ad­vi­so­ry group's nod

5 years ago

LLS backs 5 new can­cer drug projects with up to $50M; Trodelvy con­tin­ues to im­press with more TNBC da­ta

5 years ago

No­vo Nordisk to launch PhI­II obe­si­ty tri­al for oral semaglu­tide; Edi­Gene ex­tends Se­ries B with ad­di­tion­al $62M

5 years ago

Eli Lil­ly plots NDA as sec­ond JAK study backs baric­i­tinib for alope­cia area­ta; Al­ny­lam heads to FDA af­ter full vutrisir­an da­ta pan out

5 years ago

Seagen gets Au­gust PDU­FA for Pad­cev ex­pan­sions; Adap­tate pulls in new cash for gam­ma delta T cell an­ti­bod­ies

5 years ago

TG Ther­a­peu­tics pre­pares to ap­proach reg­u­la­tors with MS drug; In­vestors bet $93M on a life sci­ences tools com­pa­ny

5 years ago

Roche touts 2-year ef­fi­ca­cy da­ta for SMA ther­a­py Evrys­di; NIH funds new net­work to study flu and virus­es with ‘pan­dem­ic po­ten­tial’

5 years ago

Amy­lyx to move for­ward with ALS pro­gram in Eu­rope, but FDA wants an­oth­er look; Hu­ma­cyte adds $50M in debt fi­nanc­ing

5 years ago

Re­cur­sion lays out $300M+ goal in IPO terms; Evotec and Bris­tol My­ers team up to spin out Ger­man re­search

5 years ago

Jazz Phar­ma­ceu­ti­cals push­es to ex­pand la­bel on Xy­wav; FDA eyes Oc­to­ber for de­ci­sion on Seagen's lat­est ADC

5 years ago

Seat­tle-based Remiges Ven­tures to launch in­cu­ba­tor af­ter heavy in­vest­ment from Japan; Schrödinger signs lease on new home in Man­hat­tan

5 years ago

Bio­gen ac­quires rights for po­ten­tial Actem­ra biosim­i­lar; Roy­al­ty Phar­ma buys lumasir­an roy­al­ty stream for up to $240M

5 years ago

Vac­citech con­fi­den­tial­ly files for Nas­daq IPO — re­port; Sanofi recom­mits to so­cial caus­es, launch­es glob­al non­prof­it

5 years ago

In 1-2 punch, Mol­e­c­u­lar Tem­plates cuts first-gen can­di­date and los­es a Big Phar­ma part­ner; Charles Riv­er teams up with Va­lence to pro­vide AI dis­cov­ery plat­form

5 years ago
First page Previous page 31323334353637 Next page Last page
A service from the Financial Times